Actively Recruiting
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2025-11-18
280
Participants Needed
2
Research Sites
140 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.
CONDITIONS
Official Title
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed diffuse large B-cell lymphoma (DLBCL)
- Received at least one line of systemic antitumor therapy
- At least one measurable lesion by two dimensions
- Expected survival of at least 3 months
- Age 18 years or older and under 80 years
- Voluntary participation with signed informed consent and willingness to comply with follow-up
You will not qualify if you...
- Central nervous system lymphoma involvement
- Primary mediastinal (thymus) large B-cell lymphoma
- Only one prior line therapy and eligible for stem cell transplantation
- History of immunodeficiency
- History of severe cardiovascular disease
- History of other malignancies within 5 years before first dose
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
2
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
M
Mengbo Zhao
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here